Liquidia Technologies Inc (LQDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has a cash flow conversion efficiency ratio of 0.411x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($80.24 Million) by net assets ($195.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LQDA stock market capitalisation for the company's overall valuation and market capitalisation.
Liquidia Technologies Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Liquidia Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Liquidia Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liquidia Technologies Inc ranked by their cash flow conversion efficiency. Explore Liquidia Technologies Inc (LQDA) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Swatch Group AG
F:UHRA
|
0.012x |
|
Maxscend Microelectronics Co Ltd
SHE:300782
|
-0.021x |
|
Glacier Bancorp Inc
NYSE:GBCI
|
0.021x |
|
Taiwan Business Bank
TW:2834
|
-0.005x |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
0.003x |
|
China Coal Energy Company Limited
F:CVV
|
0.030x |
|
Fortnox AB
ST:FNOX
|
0.058x |
|
Landstar System Inc
NASDAQ:LSTR
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Liquidia Technologies Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Liquidia Technologies Inc from 2016 to 2025. View LQDA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.75 Million | $-35.69 Million | -0.797x | +34.03% |
| 2024-12-31 | $77.28 Million | $-93.42 Million | -1.209x | -37.56% |
| 2023-12-31 | $47.29 Million | $-41.56 Million | -0.879x | -177.98% |
| 2022-12-31 | $90.42 Million | $-28.59 Million | -0.316x | +39.37% |
| 2021-12-31 | $65.27 Million | $-34.03 Million | -0.521x | +31.53% |
| 2020-12-31 | $71.09 Million | $-54.14 Million | -0.762x | +44.87% |
| 2019-12-31 | $34.95 Million | $-48.28 Million | -1.382x | +18.89% |
| 2018-12-31 | $18.69 Million | $-31.83 Million | -1.703x | -336.26% |
| 2017-12-31 | $-33.69 Million | $-24.29 Million | 0.721x | -5.68% |
| 2016-12-31 | $-18.25 Million | $-13.95 Million | 0.764x | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more